Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 4;11(1):e005076.
doi: 10.1136/rmdopen-2024-005076.

Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab

Ludovic Trefond  1 , Francois Chasset  2 , Marie Jachiet  3 , Cristina Livideanu  4 , Thomas Barba  5 , Stanislas Faguer  6 , Julien Henry  7 , Gaelle Richard-Colmant  8 , Nicole Ferreira-Maldent  9 , Sandrine Roque  10 , Ruben Monteiro  11 , Kevin Chevalier  12 , Aurelia Lanteri  13 , Estibaliz Lazaro  14 , Marc Scherlinger  15 , Nicolas Belhomme  16 , Christophe Richez  17 , Claire Cazalets  18 , Laurent Sailler  19 , Nassim Ait Abdallah  20 , Jeanne de La Rochefoucauld  20 , Julien Campagne  21 , Alexandra Audemard  22 , Thomas Moulinet  23 , Noemie Abisror  24 , Nathalie Costedoat-Chalumeau  25 , Cecile Lesort  26 , Didier Bessis  27 , Diane Kottler  28 , Cecile Saint-Pastou Terrier  29 , Pierre-Yves Jeandel  30 , Sarah Lechtman  30 , Chloé Grolleau  31 , Jérome Hadjadj  24 , Bruno Pereira  32 , Perrine Smets  33 , Marc André  34 , Jean-David Bouaziz  3 , Alexis Mathian  20   35 , Zahir Amoura  20   35
Affiliations

Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab

Ludovic Trefond et al. RMD Open. .
No abstract available

Keywords: Biological Therapy; Connective Tissue Diseases; Lupus Erythematosus, Systemic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LT received support for attending meetings and/or travel from GSK, AstraZeneca, Otsuka and CSL VIFOR. FC has received grant/research support from AstraZeneca, BMS and GSK; participated in an advisory board related to lupus for AstraZeneca, GSK, Celgene, Merck, Horizon Therapeutics and Principabio; and received speaking fees and honoraria from AstraZeneca and GSK BMS related to lupus. AM has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca, GSK, Novartis and Otsuka; and received consulting fees, speaking fees and honoraria from AstraZeneca, GSK, Novartis and Otsuka. ZA has received grant/research support from GSK, AstraZeneca, Roche, Novartis and Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, Otsuka, Novartis; and received consulting fees, speaking fees and honoraria from AstraZeneca and GSK. MJ participated in an advisory board and received speaking fees from AstraZeneca and GSK related to lupus. JLR received support for attending meetings and/or travel from GSKNB has participated in an advisory board related to lupus for AstraZeneca and received speaking fees and honoraria from AstraZeneca and GSK related to lupus. NCC participated in an advisory board related to lupus for BMS and received a grant to her institution from Roche and AstraZeneca. SF has participated in an advisory board for CSL Vifor, Sanofi – Genzyme, Novartis, Alexion and AstraZeneca. EL has received a grant/research support from AstraZeneca, SOBI, NOVARTIS and GSK; participated in an advisory board related to lupus for AstraZeneca and GSK; and received speaking fees and honoraria from AstraZeneca and GSK BMS related to lupus. MA received support for attending meetings and/or travel from Novartis and CSL VIFOR. JDB received consulting fees, speaking fees and grants from Astra Zeneca. CSPT received support for attending meetings and/or travel from AstraZeneca, GSK, Novartis and Abbvie. MS is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Fresenius Kabi, Galapagos, Innate Pharma, Nordic Pharma, Novartis and Sandoz. CL received speaking fees from GSK, Astrazenaca and BMSCR and has acted as a consultant for Abbvie, AstraZeneca, Biogen, BMS, GSK, Lilly, Novartis, and Pfizer.

Figures

Figure 1
Figure 1. Kaplan–Meier estimates of the cumulative probability of herpes zoster (HZ) for patients in valaciclovir-treated and valaciclovir-untreated groups. Patients undergoing anifrolumab treatment for SLE under valaciclovir preventive treatment (red line) were compared with patients not receiving valaciclovir (blue line). Each corner in the curve represents a HZ infection. Curves were compared using log-rank tests. Crude HR was calculated using a proportional risk Cox model.
See this image and copyright information in PMC

References

    1. Pego-Reigosa JM, Nicholson L, Pooley N, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatol (Oxford) 2021;60:60–72. doi: 10.1093/rheumatology/keaa478. - DOI - PMC - PubMed
    1. Mathian A, Breillat P, Dorgham K, et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis. 2022;81:1695–703. doi: 10.1136/ard-2022-222549. - DOI - PubMed
    1. Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8 doi: 10.1136/lupus-2020-000464. - DOI - PMC - PubMed
    1. Kalunian KC, Furie R, Morand EF, et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023;75:253–65. doi: 10.1002/art.42392. - DOI - PMC - PubMed

LinkOut - more resources